Needham upgraded Amicus (FOLD) to Buy from Hold with a $14 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD:
- Positive Outlook for Amicus Therapeutics Amid Legal Developments and Patent Confidence
- Jefferies says Galafold summary judgment as expected, may facilitate settlement
- Amicus presents four-year data from PROPEL study of Pombiliti, Opfolda
- Amicus Therapeutics’ Pompe Disease Study: A Potential Game-Changer for Investors
- Amicus Therapeutics’ Global Study on Pompe Disease: A Potential Game-Changer